Accessibility Menu
PureTech Health Plc logo

PureTech Health Plc(LSE) PRTC

Current Price£1.21
Market Cap£302.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-30%
5 Year-65%
1 Year-13%
1 Month-8%
PureTech Health Plc last closing stock price
MetricPriceDate
Last closeGBX 121.002026-07-23
PureTech Health Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.97%GBX 126.002026-07-16
1 month-8.33%GBX 132.002026-06-23
3 month-1.31%GBX 122.602026-04-24
Year to date-3.2%GBX 125.002025-12-31
1 year-12.95%GBX 139.002025-07-23
3 year-45.86%GBX 223.502023-07-24
5 year-64.88%GBX 344.502021-07-23
Since inception-30.22%GBX 1.782015-06-19

PureTech Health Plc Financials at a Glance

Market Cap

£302.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.99M

Net Income (TTM)

-$56.54M

EPS (TTM)

-£0.34

P/E Ratio

-3.60

Dividend

£0.00

Beta (Volatility)

-0.07 (Low)

Price

£1.21

Volume

145,170

Open

£1.24

Previous Close

£1.24

Daily Range

£1.21 - £1.24

52-Week Range

£1.05 - £1.48

Estimated Earnings Date

Aug 27, 2026

PRTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PureTech Health Plc

PureTech Health plc is a biotechnology company focused on developing differentiated medicines for serious diseases, including inflammatory, fibrotic, and immunological conditions. The company operates through various segments, including Internal, Controlled Founded Entities, and Non-Controlled Founded Entities, aiming to address unmet medical needs.

Products and Services
  • Innovative therapies for inflammatory and fibrotic diseases
  • Development of treatments for intractable cancers
  • Research in neurological and neuropsychological disorders
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Recent partnerships enhancing research capabilities and market reach
  • Focus on expanding into new therapeutic areas and markets
Financial Highlights
  • Recent quarterly revenue of $2.82 million, showing growth potential
  • Cash and short-term investments of $278.99 million, providing financial stability
  • Current ratio of 6.59, indicating strong liquidity position
PureTech Health plc is positioned in the biotechnology sector, focusing on innovative solutions for complex health challenges. The company has a diverse product pipeline and is actively engaged in research and development to address significant medical needs. Recent financial data indicates a solid liquidity position, which may support ongoing and future projects. The company's strategic partnerships and focus on expanding its therapeutic areas could provide additional growth opportunities, making it an intriguing option for investors interested in the biotechnology field.
AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert William Henry Lyne

Website

puretechhealth.com

Headquarters

Boston, MA 02210, US

PRTC Financials

Key Financial Metrics (TTM)

Gross Margin

-471.15%

Operating Margin

-2115.41%

Net Income Margin

-2355.50%

Return on Equity

-31.83%

Return on Capital

-30.30%

Return on Assets

-20.48%

Earnings Yield

-27.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£302.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

243.42M

Volume

145.17K

Avg. Volume

528.84K

Financials (TTM)

Gross Profit

-$17.58M

Operating Income

-$234.86M

EBITDA

-$58.03M

Operating Cash Flow

-$218.18M

Capital Expenditure

-$17.03K

Free Cash Flow

-$218.20M

Cash & ST Invst.

$279.00M

Total Debt

$19.76M

PureTech Health Plc Performance Analysis

PureTech Health Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 12,679,2100.3%
20232023-12-31USD 2,678,891-78.9%
20242024-12-31USD 3,778,33341.0%
20252025-12-31USD 3,535,196-6.4%
PureTech Health Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3060.0%
Q42024-12-311298.3%
Q22025-06-30-54.0%
Q42025-12-3152.4%
PureTech Health Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.14-6.5%
20232023-12-31USD -0.1933.2%
20242024-12-31USD 0.16N/A
20252025-12-31USD -0.35N/A
PureTech Health Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31333.3%
Q22025-06-30-154.3%
Q42025-12-31-42.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.82M

+1467.5%

Gross Profit

$1.16M

+102.7%

Gross Margin

41.03%

N/A

Market Cap

£302.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£5.40M

N/A

Employees

56

N/A

Net Income

-$65.45M

-60.8%

EBITDA

-$49.17M

+28.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$279.00M

-14.7%

Total Debt

$19.76M

-85.4%

Accounts Receivable

$8.13M

+242.3%

Inventory

$0.00

-100.0%

Long Term Debt

$11.09M

-91.4%

Short Term Debt

$8.50M

+19.8%

Return on Assets

-20.48%

N/A

Return on Invested Capital

-20.13%

N/A

Free Cash Flow

-$37.87M

+7.1%

Operating Cash Flow

-$37.87M

+7.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGY.LAllergy Therapeutics plc
£0.06+4.36%
AVCT.LAvacta Group Plc
£0.68+0.57%
NIOX.LNIOX Group Plc
£0.63+1.94%
BXP.LBeximco Pharmaceuticals Limited
£0.53-0.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About PRTC

What is the current price of PureTech Health Plc?

PureTech Health Plc is trading at £1.21 per share.

What is the 52-week range for PureTech Health Plc?

Over the past 52 weeks, PureTech Health Plc has traded between £1.05 and £1.48.

How much debt does PureTech Health Plc have?

As of the most recent reporting period, PureTech Health Plc reported total debt of $14.69M.

How much cash does PureTech Health Plc have on hand?

PureTech Health Plc reported $188.89M in cash and cash equivalents in its most recent financial results.

What is PureTech Health Plc’s dividend yield?

PureTech Health Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services